Matches in SemOpenAlex for { <https://semopenalex.org/work/W2001281232> ?p ?o ?g. }
- W2001281232 endingPage "301" @default.
- W2001281232 startingPage "295" @default.
- W2001281232 abstract "Although the clinical efficacy of paclitaxel in the treatment of gastric carcinoma has not been clearly defined, recent reports have suggested a possible role in the treatment of upper gastrointestinal carcinomas in vitro and in vivo. In this study, the authors evaluated the efficacy and toxicity of a combination chemotherapy that included paclitaxel, 5-fluorouracil (5-FU), and cisplatin in the treatment of patients with advanced gastric carcinoma.Forty-one gastric carcinoma patients with metastatic disease, unresectable advanced disease, or relapsed disease were treated with the following regimen, administered every 28 days: paclitaxel 175 mg/m2 by 3-hour intravenous (i.v.) infusion on Day 1, 5-FU 750 mg/m2 by 24-hour continuous i.v. infusion on Days 1-5, and cisplatin 20 mg/m2 by 2-hour i.v. infusion on Days 1-5. Twenty-six patients had measurable disease, and 15 had evaluable disease. All patients were assessable for toxicity.Twenty-one of the 41 patients (51%; 95% confidence interval [CI], 36.5-65.7%) demonstrated an objective response, including 4 complete responses (10%; 95% CI, 3.9-22.5%). Sixty-five percent of the patients with measurable disease (17 of 26; 95% CI, 58-92.5%) and 27% of the patients with evaluable disease (4 of 15: 95% CI, 11.1-52.3%) achieved a complete response or a partial response. The median response duration was 17 weeks (range, 4-90 weeks), and the median survival duration for all patients was 26 weeks (range, 8 to 118+ weeks). The major toxicity of this treatment was myelosuppression with neutropenia of World Health Organization Grade 3 and 4 in 24% and 10% of the patients, respectively. Nonhematologic toxicity included mucositis, nausea/vomiting, diarrhea, neurotoxicity, and alopecia. Fluid retention occurred in two patients, and one patient had an anaphylatic reaction. Dose reduction was necessary for one patient, because Grade 4 neutropenia and mucositis occurred.Paclitaxel, 5-FU, and cisplatin was an active combination regimen in the treatment of advanced gastric carcinoma. The toxicity of this regimen was tolerable. Based on these findings, this combination regimen could be an attractive treatment in the preoperative setting." @default.
- W2001281232 created "2016-06-24" @default.
- W2001281232 creator A5016174704 @default.
- W2001281232 creator A5021336715 @default.
- W2001281232 creator A5041342369 @default.
- W2001281232 creator A5042141335 @default.
- W2001281232 creator A5053371139 @default.
- W2001281232 creator A5057550966 @default.
- W2001281232 creator A5063331504 @default.
- W2001281232 creator A5063563058 @default.
- W2001281232 creator A5064579248 @default.
- W2001281232 creator A5078809545 @default.
- W2001281232 date "1999-01-15" @default.
- W2001281232 modified "2023-10-10" @default.
- W2001281232 title "Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma" @default.
- W2001281232 cites W1723772693 @default.
- W2001281232 cites W1956546108 @default.
- W2001281232 cites W1979319210 @default.
- W2001281232 cites W1981534406 @default.
- W2001281232 cites W1982559524 @default.
- W2001281232 cites W1984446074 @default.
- W2001281232 cites W2008793220 @default.
- W2001281232 cites W2034288807 @default.
- W2001281232 cites W2042316019 @default.
- W2001281232 cites W2049306821 @default.
- W2001281232 cites W2057157978 @default.
- W2001281232 cites W2058979413 @default.
- W2001281232 cites W2065895095 @default.
- W2001281232 cites W2081894694 @default.
- W2001281232 cites W2145555831 @default.
- W2001281232 cites W2262251960 @default.
- W2001281232 cites W2328421677 @default.
- W2001281232 cites W4255152173 @default.
- W2001281232 doi "https://doi.org/10.1002/(sici)1097-0142(19990115)85:2<295::aid-cncr5>3.0.co;2-h" @default.
- W2001281232 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10023695" @default.
- W2001281232 hasPublicationYear "1999" @default.
- W2001281232 type Work @default.
- W2001281232 sameAs 2001281232 @default.
- W2001281232 citedByCount "129" @default.
- W2001281232 countsByYear W20012812322012 @default.
- W2001281232 countsByYear W20012812322013 @default.
- W2001281232 countsByYear W20012812322014 @default.
- W2001281232 countsByYear W20012812322015 @default.
- W2001281232 countsByYear W20012812322016 @default.
- W2001281232 countsByYear W20012812322017 @default.
- W2001281232 countsByYear W20012812322018 @default.
- W2001281232 countsByYear W20012812322019 @default.
- W2001281232 countsByYear W20012812322020 @default.
- W2001281232 countsByYear W20012812322021 @default.
- W2001281232 countsByYear W20012812322023 @default.
- W2001281232 crossrefType "journal-article" @default.
- W2001281232 hasAuthorship W2001281232A5016174704 @default.
- W2001281232 hasAuthorship W2001281232A5021336715 @default.
- W2001281232 hasAuthorship W2001281232A5041342369 @default.
- W2001281232 hasAuthorship W2001281232A5042141335 @default.
- W2001281232 hasAuthorship W2001281232A5053371139 @default.
- W2001281232 hasAuthorship W2001281232A5057550966 @default.
- W2001281232 hasAuthorship W2001281232A5063331504 @default.
- W2001281232 hasAuthorship W2001281232A5063563058 @default.
- W2001281232 hasAuthorship W2001281232A5064579248 @default.
- W2001281232 hasAuthorship W2001281232A5078809545 @default.
- W2001281232 hasBestOaLocation W20012812321 @default.
- W2001281232 hasConcept C126322002 @default.
- W2001281232 hasConcept C141071460 @default.
- W2001281232 hasConcept C2776694085 @default.
- W2001281232 hasConcept C2777292972 @default.
- W2001281232 hasConcept C2777546739 @default.
- W2001281232 hasConcept C2778239845 @default.
- W2001281232 hasConcept C2778822529 @default.
- W2001281232 hasConcept C2780456651 @default.
- W2001281232 hasConcept C2781413609 @default.
- W2001281232 hasConcept C29730261 @default.
- W2001281232 hasConcept C71924100 @default.
- W2001281232 hasConcept C90924648 @default.
- W2001281232 hasConceptScore W2001281232C126322002 @default.
- W2001281232 hasConceptScore W2001281232C141071460 @default.
- W2001281232 hasConceptScore W2001281232C2776694085 @default.
- W2001281232 hasConceptScore W2001281232C2777292972 @default.
- W2001281232 hasConceptScore W2001281232C2777546739 @default.
- W2001281232 hasConceptScore W2001281232C2778239845 @default.
- W2001281232 hasConceptScore W2001281232C2778822529 @default.
- W2001281232 hasConceptScore W2001281232C2780456651 @default.
- W2001281232 hasConceptScore W2001281232C2781413609 @default.
- W2001281232 hasConceptScore W2001281232C29730261 @default.
- W2001281232 hasConceptScore W2001281232C71924100 @default.
- W2001281232 hasConceptScore W2001281232C90924648 @default.
- W2001281232 hasIssue "2" @default.
- W2001281232 hasLocation W20012812321 @default.
- W2001281232 hasLocation W20012812322 @default.
- W2001281232 hasOpenAccess W2001281232 @default.
- W2001281232 hasPrimaryLocation W20012812321 @default.
- W2001281232 hasRelatedWork W1994109701 @default.
- W2001281232 hasRelatedWork W2012996470 @default.
- W2001281232 hasRelatedWork W2030595392 @default.
- W2001281232 hasRelatedWork W2053380829 @default.
- W2001281232 hasRelatedWork W2091461259 @default.
- W2001281232 hasRelatedWork W2149068418 @default.
- W2001281232 hasRelatedWork W2316397280 @default.